Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enbacid
- Development stage
- Unknown
- Lead developer
- AMBIENS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Enbacid is a brand name used by Ambiens Pharmaceuticals for a line of gastrointestinal combination medications marketed in India. The product line includes Enbacid-D (a combination of the proton pump inhibitor pantoprazole and the prokinetic domperidone) and Enbacid-LS (a combination of the proton pump inhibitor rabeprazole and the prokinetic levosulpiride). These formulations are approved and marketed for the treatment of gastroesophageal reflux disease (GERD), acid reflux, functional dyspepsia, gastritis, and peptic ulcers by reducing stomach acid production and improving gastrointestinal motility.
- Brand names
- EnbacidEnbacid-DEnbacid-LS
02
Targets
DRD2 (Dopamine D2 Receptor)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Enbacid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enbacid.